Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery

International Journal of Urology

Volumn 12, Issue 2, 2005, Pages 208-210

  Tadokoro, Manabu ^a   Yonese, Junji ^a   Tsukamoto, Tetsuro ^a   Okubo, Yuhei ^a   Hanada, Eiki ^a   Satoh, Yukitoshi ^a   Nakagawa, Ken ^a   Ishikawa, Yuichi ^b   Fukui, Iwao ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

Gemcitabine; Kidney pelvis; Lung; Neoplasm metastasis; Salvage therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; FEMALE; HUMAN; KIDNEY PELVIS CANCER; LUNG METASTASIS; NEPHROURETERECTOMY; NEUTROPENIA; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; KIDNEY NEOPLASMS; KIDNEY PELVIS; LUNG NEOPLASMS; MIDDLE AGED; SALVAGE THERAPY;

EID: 16244407783     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01006.x     Document Type: Article

References (3)

1. Bellmunt J, Albanell J, Paz-Ares L et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95: 751-7.
2. Tsukamoto T, Yonese J, Ishii N et al. Successful salvage chemotherapy with gemcitabine, etoposide and cisplatin for metastatic ureteral cancer: a case report. Acta Urol. Jpn 2002; 48: 427-30.
3. Siefker-Radtke AO, Walsh GL, Pisters LL et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M D Anderson Experience. J. Urol. 2004; 171: 145-8.